Literature DB >> 3525053

Prevalence of insulin deficiency among initially non-insulin-dependent middle-aged diabetic individuals.

M Laakso, H Sarlund, K Pyörälä.   

Abstract

The endogenous insulin secretion capacity of 171 insulin-treated middle-aged persons with diabetes (81 men, 90 women) of the Kuopio University Central Hospital district (population 250,000), East Finland, was measured by the C-peptide response to glucagon. The prevalence of insulin deficiency among initially non-insulin-dependent diabetic (NIDDM) individuals was calculated on the basis of those who were initially treated with diet or oral drugs and 3 yr or more after diagnosis had been treated with insulin and were insulin deficient in this study. The prevalence of complete insulin deficiency (postglucagon C-peptide undetectable) was among initially NIDDM individuals of the same region, 0.7% in men and 1.2% in women. Using the postglucagon C-peptide level of 0.20 nmol/L as a cut-off point, the prevalence of insulin deficiency was 2.0% in men and 1.9% in women and, on the basis of C-peptide level of 0.60 nmol/L, the prevalence of insulin deficiency was 3.5% in men and 2.7% in women. Our data suggest that the deterioration of insulin secretion capacity in NIDDM to the level that leads to insulin dependency occurs less often than has been previously suggested.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3525053     DOI: 10.2337/diacare.9.3.228

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  3 in total

1.  Treatment failures in patients with type 2 (non-insulin-dependent) diabetes.

Authors:  L Groop; P H Groop; S Koskimies
Journal:  Diabetologia       Date:  1988-03       Impact factor: 10.122

Review 2.  When to use insulin in the maturity onset diabetic.

Authors:  R B Tattersall; A R Scott
Journal:  Postgrad Med J       Date:  1987-10       Impact factor: 2.401

3.  Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors.

Authors:  D Giugliano; A Quatraro; G Consoli; A Minei; A Ceriello; N De Rosa; F D'Onofrio
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.